The Warwick spinout has received $5.1m in capital from investors such as Mercia Technologies to fund commercialisation of a transdermal ibuprofen patch.
Medherant, a UK-based medical technology spinout of University of Warwick focused on transdermal patches, has received £3.8m ($5.1m) in capital led by commercialisation firm Mercia Technologies.
Mercia provided £2.5m to the round and has now increased its equity stake from 11.3% to 32.4%. The remaining money was supplied by unnamed backers.
Founded in 2015, Medherant has developed adhesive patches, branded Tepi, that deliver medication through the skin to avoid side effects associated with oral drugs or injection.
The cash will…
